Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study

NCT02559856 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.

NCT NCT02559856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02559856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study
Lead sponsor
Ottawa Hospital Research Institute
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2016
Completion date
February 28, 2018
Enrollment
71 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

venous thromboembolism